护心又护肝？司美格鲁肽减重版或成代谢改善"双效王牌"

Core Viewpoint - The article discusses the significant advancements in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiovascular diseases (CVD) through the use of semaglutide, particularly its weight management version, highlighting its dual benefits in liver health and cardiovascular risk reduction [5][8][11]. Group 1: MASLD and CVD Connection - Approximately one-third of the global population is affected by MASLD, which is closely linked to obesity and type 2 diabetes mellitus (T2DM) [5][6]. - The SELECT study has established a strong correlation between MASLD and CVD, emphasizing the need for comprehensive management strategies for patients with these metabolic disorders [6][13]. Group 2: Semaglutide's Clinical Benefits - Semaglutide has been recognized as a "star drug" in the treatment of metabolic diseases due to its proven efficacy in blood sugar control, weight management, and overall metabolic improvement [6][8]. - The SELECT study included 17,604 overweight or obese participants, demonstrating that semaglutide significantly reduces the risk of major adverse cardiovascular events (MACE) by 20% compared to placebo [8][13]. - The drug also shows a 15% reduction in cardiovascular death risk and an 18% decrease in heart failure composite endpoint risk [8][11]. Group 3: Liver Health Improvements - Semaglutide's weight management version exhibits dual liver protective effects, particularly beneficial for overweight or obese patients with CVD [11][12]. - Key findings from the SELECT study indicate rapid improvement in liver enzyme levels (ALT, AST, GGT) and a significant reduction in the fatty liver index by 16.1% after 104 weeks of treatment [12][14]. Group 4: Future Implications - The findings from the SELECT study suggest that semaglutide could pave the way for a comprehensive protective strategy against cardiovascular and liver diseases in overweight and obese populations [14]. - The 2024 Obesity Treatment Guidelines emphasize the importance of focusing on metabolic health beyond mere weight loss, indicating a shift in treatment paradigms [14].